Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein

Vaccine

Volumn 30, Issue 12, 2012, Pages 2197-2205

  Bauer, Michelle J ^a   Georgousakis, Melina M ^a,g   Vu, Therese ^a   Henningham, Anna ^b   Hofmann, Andreas ^c   Rettel, Mandy ^d,e   Hafner, Louise M ^f   Sriprakash, Kadaba S ^a   McMillan, David J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^g CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

M protein; Streptococcus pyogenes; Vaccine

Indexed keywords

M PROTEIN; STREPTOCOCCUS PYOGENES VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BACTERICIDAL ACTIVITY; CIRCULAR DICHROISM; CONTROLLED STUDY; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN UNFOLDING; STREPTOCOCCUS PYOGENES; TEMPERATURE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CARRIER PROTEINS; CIRCULAR DICHROISM; CONSERVED SEQUENCE; EPITOPES; FEMALE; MICE; MICROBIAL VIABILITY; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; REPETITIVE SEQUENCES, AMINO ACID; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SYNTHETIC;

EID: 84857355393     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.115     Document Type: Article

References (48)

1. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000, 13(July (3)):470-511.
2. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet 2005, 366(July (9480)):155-168.
3. Cunningham M.W. T cell mimicry in inflammatory heart disease. Mol Immunol 2004, 40(February (14-15)):1121-1127.
4. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brandt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187(May (10)):1598-1608.
5. Hall M.A., Stroop S.D., Hu M.C., Walls M.A., Reddish M.A., Burt D.S., et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 2004, 72(May (5)):2507-2512.
6. Perez-Casal J., Caparon M.G., Scott J.R. Introduction of the emm6 gene into an emm-deleted strain of Streptococcus pyogenes restores its ability to resist phagocytosis. Res Microbiol 1992, 143(July-August (6)):549-558.
7. Smeesters P.R., McMillan D.J., Sriprakash K.S. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010, 18(June (6)):275-282.
8. Fischetti V.A. Streptococcal M-Protein-molecular design and biological behavior. Clin Microbiol Rev 1989, 2(July (3)):285-314.
9. Phillips G.N., Flicker P.F., Cohen C., Manjula B.N., Fischetti V.A. Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface. Proc Natl Acad Sci USA 1981, 78(August (8)):4689-4693.
10. Beall B., Facklam R., Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996, 34(April (4)):953-958.
11. Norton R., Smith H.V., Wood N., Siegbrecht E., Ross A., Ketheesan N. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 2004, 119(May (Suppl.)):148-151.
12. Dey N., McMillan D.J., Yarwood P.J., Joshi R.M., Kumar R., Good M.F., et al. High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2005, 40(January (1)):46-51.
13. Menon T., Whatmore A.M., Srivani S., Kumar M.P., Anbumani N., Rajaji S. Emm types of streptococcus pyogenes in Chennai. Indian J Med Microbiol 2001, 19(July-September (3)):161-162.
14. Gardiner D., Hartas J., Hibble M., Goodfellow A., Currie B., Sriprakash K.S. Molecular epidemiology of group A streptococcal infection in the Northern Territory of Australia. Adv Exp Med Biol 1997, 418:317-321.
15. Bramhachari P.V., Kaul S.Y., McMillan D.J., Shaila M.S., Karmarkar M.G., Sriprakash K.S. Disease burden due to Streptococcus dysgalactiae subsp. equisimilis (group G and C streptococci; GGS/GCS) is higher than due to S. pyogenes among Mumbai school children. J Med Microbiol 2009, (October).
16. Guilherme L., Kalil J., Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006, 39(February (1)):31-39.
17. Hu M.C., Walls M.A., Stroop S.D., Reddish M.A., Beall B., Dale J.B. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002, 70(April (4)):2171-2177.
18. Dale J.B. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 1999, 17(January (2)):193-200.
19. Dale J.B., Penfound T.A., Chiang E.Y., Walton W.J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011, 29(October (46)):8175-8178.
20. Bessen D., Fischetti V.A. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M-Protein on mucosal colonization by Group-a Streptococci. Infect Immun 1988, 56(October (10)):2666-2672.
21. Pruksakorn S., Galbraith A., Houghten R.A., Good M.F. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 1992, 149(October (8)):2729-2735.
22. Relf W.A., Cooper J., Brandt E.R., Hayman W.A., Anders R.F., Pruksakorn S., et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res 1996, 9(January-February (1)):12-20.
23. Guilherme L., Alba M.P., Ferreira F.M., Oshiro S.E., Higa F., Patarroyo M.E., et al. Anti-group A streptococcal vaccine epitope: structure, stability and its ability to interact with HLA class II molecules. J Biol Chem 2010, (December).
24. Guilherme L., Fae K.C., Higa F., Chaves L., Oshiro S.E., Freschi de Barros S., et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006, 13(June-December (2-4)):125-132.
25. Dunn L.A., McMillan D.J., Batzloff M., Zeng W., Jackson D.C., Upcroft J.A., et al. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. Vaccine 2002, 20(June (21-22)):2635-2640.
26. Olive C., Batzloff M.R., Horvath A., Wong A., Clair T., Yarwood P., et al. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002, 70(May (5)):2734-2738.
27. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997, 9(November (11)):1723-1733.
28. Pruksakorn S., Currie B., Brandt E., Phornphutkul C., Hunsakunachai S., Manmontri A., et al. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994, 6(August (8)):1235-1244.
29. Bessen D., Jones K.F., Fischetti V.A. Evidence for two distinct classes of streptococcal M protein and their relationship to rheumatic fever. J Exp Med 1989, 169(January (1)):269-283.
30. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26(October (46)):5835-5842.
31. Steer A.C., Magor G., Jenney A.W., Kado J., Good M.F., McMillan D., et al. emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009, 47(August (8)):2502-2509.
32. Yoonim N., Olive C., Pruksachatkunakorn C., Pruksakorn S. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC Microbiol 2006, 6:71.
33. Vohra H., Dey N., Gupta S., Sharma A.K., Kumar R., McMillan D., et al. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005, 156(May (4)):575-582.
34. Steer A.C., Magor G., Jenney A.W., Kado J., Good M.F., McMillan D., et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009, (June).
35. Perez-Casal J., Okada N., Caparon M.G., Scott J.R. Role of the conserved C-repeat region of the M protein of Streptococcus pyogenes. Mol Microbiol 1995, 15(March (5)):907-916.
36. Leach A.J., Morris P.S., McCallum G.B., Wilson C.A., Stubbs L., Beissbarth J., et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis 2009, 9:121.
37. Beall B., McEllistrem M.C., Gertz R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006, 44(March (3)):999-1017.
38. Smeesters P.R., McMillan D.J., Sriprakash K.S., Georgousakis M.M. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?. Expert Rev Vaccines 2009, 8(December (12)):1705-1720.
39. Georgousakis M.M., Hofmann A., Batzloff M.R., McMillan D.J., Sriprakash K.S. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein. Vaccine 2009, 27(November (48)):6799-6806.
40. McMillan D.J., Davies M.R., Good M.F., Sriprakash K.S. Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol 2004, 40(April (3)):249-256.
41. McMillan D.J., Batzloff M.R., Browning C.L., Davies M.R., Good M.F., Sriprakash K.S., et al. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004, 22(July (21-22)):2783-2790.
42. Hofmann A. ACDP-a Java application for data processing and analysis of protein circular dichroism spectra. J Appl Crystallogr 2009, 42:137-139.
43. Massell B.F., Honikman L.H., Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969, 207(February (6)):1115-1119.
44. Ouskova G., Spellerberg B., Prehm P. Hyaluronan release from Streptococcus pyogenes: export by an ABC transporter. Glycobiology 2004, 14(October (10)):931-938.
45. van de Rijn I. Streptococcal hyaluronic acid: proposed mechanisms of degradation and loss of synthesis during stationary phase. J Bacteriol 1983, 156(December (3)):1059-1065.
46. Lannergard J., Gustafsson M.C., Waldemarsson J., Norrby-Teglund A., Stalhammar-Carlemalm M., Lindahl G. The hypervariable region of Streptococcus pyogenes M protein escapes antibody attack by antigenic variation and weak immunogenicity. Cell Host Microbe 2011, 10(August (2)):147-157.
47. Penfound T.A., Chiang E.Y., Ahmed E.A., Dale J.B. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine 2010, 28(July (31)):5017-5022.
48. Sandin C., Carlsson F., Lindahl G. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes. Mol Microbiol 2006, 59(January (1)):20-30.